Login to Your Account



Sure bets or 'lung' shots? New data leave uncertain the better bets in combos

By Randy Osborne
Staff Writer

Tuesday, September 8, 2015
With Bristol-Myers Squibb Co. (BMS) as well as Roche AG and Astrazeneca plc offering new data at the World Conference on Lung Cancer in Denver, analysts were hard pressed to pick the best wager, though one survey of people on the buy side suggested that they found BMS's combination therapy most impressive.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription